June 29

AMSTERDAM, June 29, 2011 - Data Presented at the 79thEuropean Atherosclerosis Society Meeting Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today released data showing that its gene therapy Glybera (alipogene tiparvovec) significantly reduces the risk of pancreatitis in patients with Lipoprotein Lipase Deficiency (LPLD).

ROLLE, Switzerland, June 29, 2011 - - Hundreds of millions of patients affected worldwide, both in developing and high income countries As International experts gather in Geneva for the first International Conference on Prevention and Infection Control(1), CareFusion announces the organization of an adjunct symposium gathering International experts to address standards to reduce health care-associated infections (HCAIs).

TEL AVIV, Israel, June 29, 2011 - Abbott (NYSE: ABT) and Yeda Research and Development Company Ltd., the commercial arm of the Weizmann Institute of Science (WIS), have signed a three-year agreement in which Abbott will fund research programs at the Weizmann Institute of Science in selected health care fields.

GENEVA, June 29, 2011 - Extended Indication would Include Patients with Early Signs of Multiple Sclerosis Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that it has submitted an application to the European Medicines Agency (EMA) to extend the indication of Rebif[R], its leading treatment for multiple sclerosis (MS).

LONDON, June 29, 2011 - Futurestep, a Korn/Ferry Company (NYSE: KFY) has announced advancements and additions to its EMEA organization to address growing demand for its solutions in the region.